In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Elevated HDL-C is associated with adverse cardiovascular outcomes

Session HDL cholesterol - A moving target

Speaker Marc Allard-Ratick

Event : ESC Congress 2018

  • Topic : preventive cardiology
  • Sub-topic : Lipids, Other
  • Session type : Advances in Science

Authors : M Allard-Ratick (Atlanta,US), J Khambhati (Atlanta,US), M Topel (Atlanta,US), P Sandesara (Atlanta,US), L Sperling (Atlanta,US), A Quyyumi (Atlanta,US)

M. Allard-Ratick1 , J. Khambhati1 , M. Topel1 , P. Sandesara1 , L. Sperling1 , A. Quyyumi1 , 1Emory University, Cardiology - Atlanta - United States of America ,

Lipids, Other

European Heart Journal ( 2018 ) 39 ( Supplement ), 3

Background: Previous studies have shown reduced cardiovascular (CV) risk with increasing high-density lipoprotein cholesterol (HDL-C) levels. However, at elevated HDL-C levels (>60mg/dl), its atheroprotective functions, such as cholesterol efflux and anti-oxidant capacity, may be impaired. The association between high levels of HDL-C and adverse outcomes remains unclear.

Purpose: To study the relationship between elevated HDL-C levels (>60mg/dl) and adverse CV outcomes in an at-risk population.

Methods: Participants included 5,965 individuals (mean age 63.3±12.4 years, 35% female, 23% African American) enrolled in the cardiovascular biobank. Restricted cubic spline curves were used to examine the potential non-linear association between HDL-C and adverse outcomes using HDL-C of 50mg/dL as reference. Individuals were also stratified by HDL-C categories (<30, 31–40, 41–50, 51–60 and ≥60 mg/dL) and a Cox proportional hazards model was used to examine the association between HDL-C and adverse outcomes, with HDL-C 51–60 mg/dL as the reference group. All models were adjusted for age, race, sex, body mass index, hypertension, smoking, triglycerides, low density lipoprotein cholesterol, heart failure history, myocardial infarction (MI) history, diabetes, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use, beta blocker use, statin use, aspirin use, estimated glomerular filtration rate, obstructive coronary artery disease.

Results: Over a median follow-up of 3.9 years (interquartile range 1.6 to 6.6 years), there were 769 CV death/non-fatal MI events. Restricted cubic spline regression models demonstrated a “U-shaped” association between HDL-C and CV death/non-fatal MI (Figure 1) and all-cause mortality (not pictured). Individuals with HDL-C <30 mg/dL (n=825) and ≥60 mg/dL (n=570) had an increased risk of all-cause mortality and CV death/non-fatal MI (HR 1.62; 95% CI=1.16–2.26, p=0.005 and HR 1.44; 95% CI = 1.01–2.06, p=0.04 respectively) after adjusting for aforementioned variables.

Conclusion: Elevated HDL-C levels are paradoxically associated with an increased risk of adverse CV events in an at-risk population, suggesting dysfunctional HDL and impaired atheroprotection.

Association of HDL-C and CV death/MI

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are